Etoposide in Treating Patients With Advanced Ovarian or Cervical Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00002478|
Recruitment Status : Terminated
First Posted : June 9, 2004
Last Update Posted : June 10, 2013
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of etoposide in treating patients who have refractory, recurrent, or metastatic ovarian or cervical cancer.
|Condition or disease||Intervention/treatment||Phase|
|Cervical Cancer Ovarian Cancer||Drug: etoposide||Phase 2|
OBJECTIVES: I. Determine the efficacy of prolonged oral etoposide (VP-16) in patients with advanced ovarian epithelial or cervical cancer. II. Evaluate the frequency and severity of observed adverse effects in this patient population treated with prolonged oral VP-16.
OUTLINE: Patients receive etoposide by mouth once daily on days 1-21 every 4 weeks. Patients with responding disease continue treatment for up to 12 months in the absence of disease progression or unacceptable toxicity. Patients with stable disease continue treatment for up to 6 months in the absence of disease progression or unacceptable toxicity.
PROJECTED ACCRUAL: If 4-6 responses are observed in the first 25 patients, an additional 15 patients will be entered. The estimated duration of the study is 8 months.
|Study Type :||Interventional (Clinical Trial)|
|Official Title:||Phase II Study of Prolonged Oral VP-16 for Advanced Ovarian Epithelial and Cervical Cancer|
|Study Start Date :||June 1993|
|Actual Primary Completion Date :||October 2003|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00002478
Show 47 Study Locations
|Study Chair:||Peter G. Rose, MD||University Hospitals Seidman Cancer Center|